BenzingaAugust 12, 2026 at 8:18 AM NY2 Months Ago
Stephens & Co. Maintains Overweight on Amrize, Lowers Price Target to $54
Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
